Published: Sat, May 20, 2017
Money | By Armando Alvarado

Brokers Release Average Price Target Of 7.83 On Novavax, Inc. (NASDAQ:NVAX)

When it comes to the Analysis of a Stock, Price Target plays a vital role. State Board of Administration of Florida Retirement System owned approximately 0.05% of Novavax worth $179,000 at the end of the most recent reporting period. During the same period in the prior year, the business posted ($0.29) earnings per share.

Novavax, a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

The share price of the company (NASDAQ:NVAX) was down -8.85%, with a high of 1.11 during the day and the volume of Novavax, Inc. shares traded was 7489603.

ICON Public Limited Company (NASDAQ:ICLR) belongs to Healthcare sector, recorded a price change of 1.56% in last trade close. Piermont Capital Management Inc. now owns 158,788 shares of the biopharmaceutical company's stock worth $330,000 after buying an additional 13,370 shares during the last quarter.

CONSOL Energy Inc. (CNX) exchanged hands at an unexpectedly low level of 2.83 million shares over the course of the day.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) ended its day at $3.99 with the rising stream of 3.64% and its total traded volume was 4.49 million shares less than the average volume. The Company has 52-week high of $8.49 and 52-week low of $0.73.

West Indies chasing 304 to win Test series with Pakistan
A swift end to the match had looked likely as Vishaul Singh and Shane Dowrich both fell to Shah just after lunch. That effort put him into the record books for the most catches ever by a Pakistani fielder in a Test series.

Its latest closing price kept its distance from the SMA50 at 7.67% and 3.68% compared with the SMA 20 while it was down/up 10.44% from the average-price of 200 days. The stock's market cap is $305.20 million. Novavax posted earnings of ($0.29) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 37.9%.

Maximum and minimum EPS estimate for the current quarter is projected at $-0.15 and $-0.17, respectively, according to 7 analysts. The Return on Equity (ROE) value stands at -787.4%. According to these analysts, the Low Revenue Estimate for Novavax, 4.5 Million and the High Revenue Estimate is 6.6 Million.

The company is expected to report earnings of $-0.16 a share for the next quarter. The firm's revenue for the quarter was down 7.7% compared to the same quarter previous year. Currently, Novavax, profit margin for the 12 months is at -1466.36%. Piermont Capital Management Inc. boosted its stake in Novavax by 9.2% in the third quarter. Cantor Fitzgerald reiterated a "hold" rating and set a $2.00 target price on shares of Novavax in a research note on Friday, January 20th. Finally, FBR & Co reaffirmed an "outperform" rating and issued a $12.00 target price on shares of Novavax in a report on Wednesday, January 18th.

Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Novavax, Inc. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. Volatility of the stock was 11.46% for the week while for the month booked as 8.11%.

In other news, insider Stanley C. Erck purchased 50,000 shares of the company's stock in a transaction that occurred on Thursday, May 11th. While it's Return on Investment (ROI) value is 0%. Following the completion of the acquisition, the insider now directly owns 128,279 shares of the company's stock, valued at $107,754.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

EPS calculates as net profit divided by No. of outstanding shares.

Like this: